Phase 1 Multiple sclerosis trials recruiting now

All Multiple sclerosis trials, every phase

Other phases for Multiple sclerosis

Phase 1 Multiple sclerosis trials

• A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.
  NCT05620940 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: Male · 1 location
• A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis
  NCT04121468 · Phase: Phase 1, Phase 2 · Ages: 10 Years to 25 Years · Sex: All (male and female) · 1 location
• A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
  NCT07304154 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 8 locations
• A Study of AZD0120 in Autoimmune Diseases
  NCT07295847 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 22 locations
• A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
  NCT06138132 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
  NCT06249438 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis
  NCT07660614 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 5 locations
• A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
  NCT07100119 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 12 locations
• A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
  NCT06680037 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
  NCT05704361 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 32 locations
• AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis
  NCT05832515 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
  NCT06063850 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 36 locations
• AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
  NCT06665165 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis
  NCT06592703 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
  NCT07224373 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 19 locations
• An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
  NCT06617793 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 18 locations
• Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
  NCT05359653 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
  NCT03759522 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
  NCT07361094 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 2 locations
• CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
  NCT07305116 · Phase: Phase 1 · Ages: 3 Years and older · Sex: All (male and female) · 1 location
• Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
  NCT05849467 · Phase: Phase 1 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
  NCT06671236 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Deep Brain Stimulation for Refractory Trigeminal Neuralgia with a Pontine Lesion
  NCT05451251 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
  NCT05532943 · Phase: Phase 1, Phase 2 · Ages: 20 Years to 65 Years · Sex: All (male and female) · 1 location
• Exploring the Utility of [18F]3F4AP for Demyelination Imaging
  NCT06999434 · Phase: Phase 1 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
  NCT06351592 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects
  NCT04699747 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• MB-CART2019.1 in Refractory Multiple Sclerosis
  NCT07178431 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Molecular Imaging of NET Using [C-11]MRB-PET in MS
  NCT03207464 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis
  NCT06552611 · Phase: Phase 1 · Ages: 21 Years to 70 Years · Sex: All (male and female) · 1 location
• Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
  NCT07139743 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 7 locations
• Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
  NCT06675864 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 18 locations
• PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
  NCT02649985 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
  NCT07085676 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 2 locations
• SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
  NCT03783416 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
  NCT07587125 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
  NCT07526493 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS
  NCT05003388 · Phase: Phase 1 · Ages: No age limits stated · Sex: All (male and female) · 2 locations
• Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
  NCT05395624 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 9 locations
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients
  NCT07085507 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
  NCT07287202 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• Sapu003 in Advanced mTOR-sensitive Solid Tumors
  NCT07369505 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
  NCT07221240 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
  NCT03109288 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 260 locations
• Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
  NCT07477639 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis
  NCT02912897 · Phase: Phase 1 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 1 location
• Vancomycin Study in Multiple Sclerosis (MS)
  NCT05539729 · Phase: Phase 1 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.